<DOC>
	<DOCNO>NCT02897479</DOCNO>
	<brief_summary>This Phase II , open-label , multicenter study Savolitinib administer orally per day ( QD ) locally advanced/metastatic PSC patient MET Exon 14 mutation . The targeted population patient MET Exon 14 mutation fail prior systemic therapy ( y ) , unwilling unable receive chemotherapy . Pathological diagnosis confirm retrospectively central pathological laboratory .</brief_summary>
	<brief_title>A Phase II Study HMPL-504 Lung Sarcomatoid Carcinoma</brief_title>
	<detailed_description>Savolitinib administrate 600mg per day ( QD ) . The treatment discontinue patient experience disease progression , death experience unacceptable toxicity , whichever occur first . A cycle study treatment define 21 day continuous dosing .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<criteria>1.Fully understood study voluntarily sign Informed Consent Form 2.Age &gt; 18 year 3.Histologically cytologically document locally advanced Metastatic pulmonary sarcomatoid carcinoma ( PSC ) patient MET Exon 14 mutation fail piror systemic therapy ( y ) , unwilling unable receive chemotherapy 4.Patient measurable disease per RECIST1.1 5.ECOG performance status 0 , 1 6.Expected survival &gt; 12 week 1.Coexisting malignancy malignancy diagnose within last 3 year lung cancer exception adequately treat skin basal cell carcinoma cervical cancer situ . 2.Any anticancer therapy , include chemotherapy , hormonal therapy , biologic therapy radiotherapy within 3weeks prior initiation study treatment , receive TKI ( ex . EGFRTKI ) treatment within 2 week prior initiation study treatment 3.Palliative radiation bone metastasis within 2 week prior initiation study treatment 4.Herbal therapy within 1 week prior initiation study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>